{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:21:55Z","timestamp":1793409715539,"version":"4.5.0"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Rheumatoid arthritis (RA), a chronic autoimmune disorder, imposes a substantial global health burden through elevated disability rates, systemic complications, and socioeconomic consequences. Chronic synovitis and progressive joint destruction characterize this disease, driven by dysregulated innate and adaptive immune responses that amplify synovial inflammation, osteoclastogenesis, and irreversible tissue damage. Aberrant activation of interleukin (IL) -1 family cytokines critically contributes to RA pathogenesis. These cytokines mediate dual mechanisms: pro-inflammatory agonists like IL-1\u03b2, IL-18, and IL-36 accelerate disease progression, whereas insufficient levels of anti-inflammatory antagonists such as IL-1Ra and IL-37 disrupt the balance required to suppress pathogenic cascades. Clinical trials evaluating IL-1-targeting biologics\u2014including anakinra and canakinumab\u2014have demonstrated robust early efficacy. However, late-stage interventions exhibit diminished therapeutic returns, largely due to irreversible joint damage and compensatory activation of redundant cytokine networks. These findings emphasize the need for precise patient stratification. Single-pathway IL-1 inhibition faces inherent limitations, driving the development of multi-target strategies to counteract cytokine redundancy and reduce therapeutic resistance. This review systematically analyzes the mechanistic roles of IL-1 family cytokines in RA, evaluates clinical outcomes and safety profiles of IL-1-targeted therapies, and proposes innovative strategies to advance RA treatment.<\/jats:p>","DOI":"10.3389\/fphar.2025.1577628","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:46:01Z","timestamp":1748583961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis"],"prefix":"10.3389","volume":"16","author":[{"given":"Kexin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoge","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s11095-013-1118-0","article-title":"IL-1Ra and its delivery strategies: inserting the association in perspective","volume":"30","author":"Akash","year":"2013","journal-title":"Pharm. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/03009742.2017.1324909","article-title":"Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sj\u00f6gren\u2019s syndrome (secondary Sj\u00f6gren\u2019s syndrome) focusing on autoimmune rheumatic diseases","volume":"47","author":"Alani","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1257045","DOI":"10.3389\/fmed.2023.1257045","article-title":"Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study","volume":"10","author":"Alexeeva","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1\u03b2 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","article-title":"Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders","volume":"13","author":"Arnold","year":"2022","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11125","DOI":"10.3390\/ijms241311125","article-title":"IL-18 in autoinflammatory diseases: focus on adult onset still disease and macrophages activation syndrome","volume":"24","author":"Baggio","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10067-010-1654-5","article-title":"Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis","volume":"30","author":"Bao","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1086\/422827","article-title":"A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis","volume":"75","author":"Begovich","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0152474","DOI":"10.1371\/journal.pone.0152474","article-title":"Redundancy of IL-1 isoform signaling and its implications for arterial remodeling","volume":"11","author":"Beltrami-Moreira","year":"2016","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4049\/jimmunol.1502124","article-title":"In vivo expansion of activated Foxp3+ regulatory T cells and establishment of a type 2 immune response upon IL-33 treatment protect against experimental arthritis","volume":"197","author":"Biton","year":"2016","journal-title":"J. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/imr.12606","article-title":"The family of the interleukin-1 receptors","volume":"281","author":"Boraschi","year":"2018","journal-title":"Immunol. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1136\/annrheumdis-2013-204591","article-title":"A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides","volume":"74","author":"Bossini-Castillo","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36\u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn\u2019s disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/annrheumdis-2016-210630","article-title":"IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro","volume":"76","author":"Boutet","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"112357","DOI":"10.1016\/j.intimp.2024.112357","article-title":"The impacts of obesity in rheumatoid arthritis and insights into therapeutic purinergic modulation","volume":"136","author":"Braga","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::Aid-art15>3.0.Co;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum."},{"key":"B18","first-page":"1103","article-title":"Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial","volume":"31","author":"Bresnihan","year":"2004","journal-title":"J. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1093\/rheumatology\/kev269","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatol. (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"55","author":"Cavalli","year":"2016","journal-title":"Rheumatol. (Oxford)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1073\/pnas.0812690106","article-title":"The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1","volume":"106","author":"Cayrol","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.3390\/ijms221910659","article-title":"Vitamin D and rheumatic diseases: a review of clinical evidence","volume":"22","author":"Charoenngam","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/jpp\/rgae020","article-title":"Schisandrin B ameliorates adjuvant-induced arthritis in rats via modulation of inflammatory mediators, oxidative stress, and HIF-1\u03b1\/VEGF pathway","volume":"76","author":"Chen","year":"2024","journal-title":"J. Pharm. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","volume":"15","author":"Chen","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/s0140-6736(20)32340-0","article-title":"Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Cieza","year":"2021","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"B29","first-page":"225","article-title":"Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis","volume":"30","author":"Cohen","year":"2003","journal-title":"J. Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Collaborators","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102735","DOI":"10.1016\/j.autrev.2020.102735","article-title":"Beyond the joints, the extra-articular manifestations in rheumatoid arthritis","volume":"20","author":"Conforti","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00003246-200201000-00048","article-title":"Cytokine signaling in sepsis: redundancy, crosstalk, and regulatory mechanisms","volume":"30","author":"Cooney","year":"2002","journal-title":"Crit. Care Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/ar1893","article-title":"Epstein-Barr virus and rheumatoid arthritis: is there a link?","volume":"8","author":"Costenbader","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2119\/molmed.2017.00081","article-title":"Dense genotyping of immune-related regions identifies loci for rheumatoid arthritis risk and damage in African Americans","volume":"23","author":"Danila","year":"2017","journal-title":"Mol. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13075-019-2008-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects","volume":"21","author":"Danto","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"998281","DOI":"10.3389\/fmed.2022.998281","article-title":"Off-label use of canakinumab in pediatric rheumatology and rare diseases","volume":"9","author":"Del Giudice","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e101954","DOI":"10.1371\/journal.pone.0101954","article-title":"Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis","volume":"9","author":"Derer","year":"2014","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3899\/jrheum.131464","article-title":"Tumor necrosis factor-\u03b1 inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study","volume":"41","author":"Desai","year":"2014","journal-title":"J. Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1206","DOI":"10.1002\/cti2.1206","article-title":"Inhibition of interleukin-1\u03b2 signalling promotes atherosclerotic lesion remodelling in mice with inflammatory arthritis","volume":"9","author":"Dragoljevic","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jaad.2023.02.040","article-title":"Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study","volume":"89","author":"Elewski","year":"2023","journal-title":"J. Am. Acad. Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ng.2462","article-title":"High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis","volume":"44","author":"Eyre","year":"2012","journal-title":"Nat. Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"114099","DOI":"10.1016\/j.celrep.2024.114099","article-title":"Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling","volume":"43","author":"Fields","year":"2024","journal-title":"Cell. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1189\/jlb.3RI1014-495R","article-title":"Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions","volume":"97","author":"Gabay","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.47360\/1995-4484-2024-81-89","article-title":"Dynamics of modified cardiovascular risk factors in patients with rheumatoid arthritis on the background of 5-year therapy with an interleukin 6 receptor inhibitor","volume":"62","author":"Gerasimova","year":"2024","journal-title":"Nauchno-Prakticheskaya Revmatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"152461","DOI":"10.1016\/j.semarthrit.2024.152461","article-title":"Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports","volume":"67","author":"Goldman","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A phase II open-label study of Bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/ahmt.S109495","article-title":"Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition","volume":"8","author":"Grevich","year":"2017","journal-title":"Adolesc. Health Med. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/ibd\/izac161","article-title":"Racial difference in efficacy of golimumab in ulcerative colitis","volume":"29","author":"Greywoode","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/annrheumdis-2018-214725","article-title":"Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population","volume":"78","author":"Guo","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10753-021-01531-x","article-title":"Long non-coding RNA NEAT1 knockdown alleviates rheumatoid arthritis by reducing IL-18 through p300\/CBP repression","volume":"45","author":"Guo","year":"2022","journal-title":"Inflammation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"7933453","DOI":"10.1155\/2021\/7933453","article-title":"IL-38 and IL-36 target autophagy for regulating synoviocyte proliferation, migration, and invasion in rheumatoid arthritis","volume":"2021","author":"Hao","year":"2021","journal-title":"Dis. Markers"},{"key":"B57","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jcpt.13142","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis","volume":"45","author":"Ho Lee","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.actbio.2024.06.048","article-title":"IL-1ra loaded chondroitin sulfate-functionalized microspheres for minimally invasive treatment of intervertebral disc degeneration","volume":"185","author":"Hong","year":"2024","journal-title":"Acta Biomater."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.cjca.2020.01.003","article-title":"Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors: a national cohort study","volume":"36","author":"Hsieh","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1089272","DOI":"10.3389\/fphar.2023.1089272","article-title":"Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: a meta-analysis","volume":"14","author":"Hu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1002\/art.21419","article-title":"Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles","volume":"52","author":"Irigoyen","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/art.20219","article-title":"Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis","volume":"50","author":"Iwahashi","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B64","doi-asserted-by":"publisher","first-page":"631603","DOI":"10.3389\/fimmu.2021.631603","article-title":"IL-33 gene polymorphisms as potential biomarkers of disease susceptibility and response to TNF inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients","volume":"12","author":"Iwaszko","year":"2021","journal-title":"Front. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1128\/iai.01618-13","article-title":"Inflammatory bone loss in experimental periodontitis induced by Aggregatibacter actinomycetemcomitans in interleukin-1 receptor antagonist knockout mice","volume":"82","author":"Izawa","year":"2014","journal-title":"Infect. Immun."},{"key":"B66","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41419-018-0570-5","article-title":"GATA4 regulates angiogenesis and persistence of inflammation in rheuma toid arthritis","volume":"9","author":"Jia","year":"2018","journal-title":"Cell. Death and Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"eabo0686","DOI":"10.1126\/scitranslmed.abo0686","article-title":"Granzyme K(+) CD8 T cells form a core population in inflamed human tissue","volume":"14","author":"Jonsson","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"B70","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jocn.2024.01.009","article-title":"The efficacy and safety of interleukin-1 receptor antagonist in stroke patients: a systematic review","volume":"120","author":"Kazmi","year":"2024","journal-title":"J. Clin. Neurosci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e61841","DOI":"10.7554\/eLife.61841","article-title":"Induction of the IL-1RII decoy receptor by NFAT\/FOXP3 blocks IL-1\u03b2-dependent response of Th17 cells","volume":"10","author":"Kim","year":"2021","journal-title":"Elife"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.4110\/in.2024.24.e21","article-title":"IL-1 receptor dynamics in immune cells: Orchestrating immune precision and balance","volume":"24","author":"Kim","year":"2024","journal-title":"Immune Netw."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.4049\/jimmunol.0803007","article-title":"The mechanism of osteoclast differentiation induced by IL-1","volume":"183","author":"Kim","year":"2009","journal-title":"J. Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1016\/j.ajpath.2015.07.017","article-title":"Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis","volume":"185","author":"Kim","year":"2015","journal-title":"Am. J. Pathol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/joim.13058","article-title":"The importance of differences; on environment and its interactions with genes and immunity in the causation of rheumatoid arthritis","volume":"287","author":"Klareskog","year":"2020","journal-title":"J. Intern Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jdsr.2023.08.002","article-title":"Periodontitis and periodontopathic bacteria as risk factors for rheumatoid arthritis: a review of the last 10 years","volume":"59","author":"Kobayashi","year":"2023","journal-title":"Jpn. Dent. Sci. Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/ard-2022-223396","article-title":"Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis","volume":"82","author":"Kugler","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3892\/ijmm.2012.883","article-title":"IL-33 regulates TNF-\u03b1 dependent effects in synovial fibroblasts","volume":"29","author":"Kunisch","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"166766","DOI":"10.1016\/j.jmb.2020.166766","article-title":"Structure-based development of human interleukin-1\u03b2-specific antibody that simultaneously inhibits binding to both IL-1RI and IL-1RAcP","volume":"433","author":"Kuo","year":"2021","journal-title":"J. Mol. Biol."},{"key":"B83","first-page":"837","article-title":"The effect of anti-TNF treatment on osteoblastogenesis in ankylosing spondylitis: the number of circulating osteoblast-lineage cells in peripheral blood decreased after infliximab therapy in patients with ankylosing spondylitis","volume":"35","author":"Kwon","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cyto.2015.10.005","article-title":"Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis","volume":"77","author":"Lee","year":"","journal-title":"Cytokine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.imlet.2016.02.011","article-title":"IL-1 receptor antagonist (IL-1Ra)-Fc ameliorate autoimmune arthritis by regulation of the Th17 cells\/Treg balance and arthrogenic cytokine activation","volume":"172","author":"Lee","year":"","journal-title":"Immunol. Lett."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e141008","DOI":"10.1172\/jci141008","article-title":"IL-1\u03b2-driven osteoclastogenic Tregs accelerate bone erosion in arthritis","volume":"131","author":"Levescot","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B88","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12958-021-00811-3","article-title":"Recombinant human IL-37 inhibited endometriosis development in a mouse model through increasing Th1\/Th2 ratio by inducing the maturation of dendritic cells","volume":"19","author":"Li","year":"2021","journal-title":"Reprod. Biol. Endocrinol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"4297354","DOI":"10.1155\/2020\/4297354","article-title":"Blocking interleukin-33 alleviates the joint inflammation and inhibits the development of collagen-induced arthritis in mice","volume":"2020","author":"Li","year":"2020","journal-title":"J. Immunol. Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/jpm12081265","article-title":"Pharmacogenomics of monoclonal antibodies for the treatment of rheumatoid arthritis","volume":"12","author":"Lim","year":"2022","journal-title":"J. Pers. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"103001","DOI":"10.1016\/j.jaut.2023.103001","article-title":"Gut microbiota in pre-clinical rheumatoid arthritis: from pathogenesis to preventing progression","volume":"141","author":"Lin","year":"2023","journal-title":"J. Autoimmun."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbalip.2019.05.009","article-title":"IL-37 inhibits the maturation of dendritic cells through the IL-1R8-TLR4-NF-\u03baB pathway","volume":"1864","author":"Liu","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4049\/jimmunol.1901176","article-title":"IL-37 represses the autoimmunity in myasthenia gravis via directly targeting follicular Th and B cells","volume":"204","author":"Liu","year":"2020","journal-title":"J. Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/art.42089","article-title":"Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019","volume":"74","author":"Long","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1189\/jlb.3RI1214-595R","article-title":"New dog and new tricks: evolving roles for IL-33 in type 2 immunity","volume":"97","author":"Lott","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/ijms23052871","article-title":"Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments","volume":"23","author":"Maeda","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1749-799x-4-17","article-title":"The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study","volume":"4","author":"Malviya","year":"2009","journal-title":"J. Orthop. Surg. Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1759720x20959575","DOI":"10.1177\/1759720x20959575","article-title":"The off-label use of anakinra in pediatric systemic autoinflammatory diseases","volume":"12","author":"Maniscalco","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","article-title":"Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis","volume":"455","author":"Mateen","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"B100","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaip.2020.07.058","article-title":"Canakinumab lacks efficacy in treating adult patients with moderate to severe chronic spontaneous urticaria in a phase II randomized double-blind placebo-controlled single-center study","volume":"9","author":"Maul","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B101","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12967-021-03071-2","article-title":"IL-18 binding protein suppresses IL-17-induced osteoclastogenesis and rectifies type 17 helper T cell\/regulatory T cell imbalance in rheumatoid arthritis","volume":"19","author":"Min","year":"2021","journal-title":"J. Transl. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.55563\/clinexprheumatol\/hjvvf1","article-title":"Interleukin-18 binding protein regulates the apoptosis and necroptosis of fibroblast-like synoviocytes and chondrocytes in rheumatoid arthritis","volume":"41","author":"Min","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3899\/jrheum.170703","article-title":"Filling the gap: toward a disease activity tool for systemic juvenile idiopathic arthritis","volume":"45","author":"Minoia","year":"2018","journal-title":"J. Rheumatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/jmcb\/mjw006","article-title":"Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses","volume":"8","author":"Mora","year":"2016","journal-title":"J. Mol. Cell. Biol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/labinvest.3780351","article-title":"Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation","volume":"81","author":"Morel","year":"2001","journal-title":"Lab. Invest."},{"key":"B106","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s10495-014-1073-1","article-title":"Toll\/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways","volume":"20","author":"Narayanan","year":"2015","journal-title":"Apoptosis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2017.00282","article-title":"Revisiting the role of interleukin-1 pathway in osteoarthritis: interleukin-1\u03b1 and -1\u03b2, and NLRP3 inflammasome are not involved in the pathological features of the murine menisectomy model of osteoarthritis","volume":"8","author":"Nasi","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.molimm.2011.08.020","article-title":"Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis","volume":"49","author":"Niu","year":"2011","journal-title":"Mol. Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1111\/bcp.14361","article-title":"The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis","volume":"86","author":"Nnane","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J. Rheumatol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B112","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ajhg.2016.06.019","article-title":"Contribution of a non-classical HLA gene, HLA-DOA, to the risk of rheumatoid arthritis","volume":"99","author":"Okada","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"B113","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ng.2231","article-title":"Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population","volume":"44","author":"Okada","year":"2012","journal-title":"Nat. Genet."},{"key":"B114","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00281-022-00912-0","article-title":"Genetics of rheumatoid arthritis","volume":"44","author":"Padyukov","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1002\/art.20553","article-title":"A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis","volume":"50","author":"Padyukov","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.41612","article-title":"Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis","volume":"73","author":"Pardeo","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20182431","article-title":"IL-38 restrains inflammatory response of collagen-induced arthritis in rats via SIRT1\/HIF-1\u03b1 signaling pathway","volume":"40","author":"Pei","year":"2020","journal-title":"Biosci. Rep."},{"key":"B120","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1063-4584(96)80009-4","article-title":"The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation","volume":"4","author":"Pelletier","year":"1996","journal-title":"Osteoarthr. Cartil."},{"key":"B121","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1172\/jci1379","article-title":"Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells","volume":"101","author":"Puren","year":"1998","journal-title":"J. Clin. Invest."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.3389\/fmicb.2019.02482","article-title":"Interleukin-37 ameliorates influenza pneumonia by attenuating macrophage cytokine production in a MAPK-dependent manner","volume":"10","author":"Qi","year":"2019","journal-title":"Front. Microbiol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.3390\/ijerph19095690","article-title":"Counteractive effects of IL-33 and IL-37 on inflammation in osteoarthritis","volume":"19","author":"Rai","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B124","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ng.1076","article-title":"Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis","volume":"44","author":"Raychaudhuri","year":"2012","journal-title":"Nat. Genet."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1172\/jci118636","article-title":"The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis","volume":"97","author":"Reboul","year":"1996","journal-title":"J. Clin. Invest."},{"key":"B127","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/art.41630","article-title":"HLA-B*08 identified as the most prominently associated major histocompatibility complex locus for anti-carbamylated protein antibody-positive\/anti-cyclic citrullinated peptide-negative rheumatoid arthritis","volume":"73","author":"Regueiro","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/cpt.3147","article-title":"A randomized phase I study of the anti-interleukin-33 antibody Tozorakimab in healthy adults and patients with chronic obstructive pulmonary disease","volume":"115","author":"Reid","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B129","doi-asserted-by":"publisher","first-page":"152382","DOI":"10.1016\/j.imbio.2023.152382","article-title":"IL-37 alleviates TNF-\u03b1-induced pyroptosis of rheumatoid arthritis fibroblast-like synoviocytes by inhibiting the NF-\u03baB\/GSDMD signaling pathway","volume":"228","author":"Ren","year":"2023","journal-title":"Immunobiology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12079-019-00544-4","article-title":"A comprehensive pathway map of IL-18-mediated signalling","volume":"14","author":"Rex","year":"2020","journal-title":"J. Cell. Commun. Signal"},{"key":"B131","doi-asserted-by":"publisher","first-page":"106401","DOI":"10.1016\/j.intimp.2020.106401","article-title":"Association between IL1B polymorphisms and the risk of rheumatoid arthritis","volume":"83","author":"Rong","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/ar127","article-title":"Bone loss. Factors that regulate osteoclast differentiation: an update","volume":"2","author":"Roux","year":"2000","journal-title":"Arthritis Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B134","doi-asserted-by":"publisher","first-page":"403","DOI":"10.55563\/clinexprheumatol\/phsqg7","article-title":"Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial","volume":"39","author":"Ruscitti","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"e1002901","DOI":"10.1371\/journal.pmed.1002901","article-title":"Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): a multicentre, open-label, randomised controlled trial","volume":"16","author":"Ruscitti","year":"2019","journal-title":"PLoS Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2174\/1573397112666160404124655","article-title":"The effect of TNF\u03b1-inhibitors on cardiovascular events in patients with rheumatoid arthritis: an updated systematic review of the literature","volume":"12","author":"Sattin","year":"2016","journal-title":"Curr. Rheumatol. Rev."},{"key":"B138","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"B139","first-page":"88","article-title":"A randomised trial evaluating anakinra in early active rheumatoid arthritis","volume":"34","author":"Scott","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1517\/14740338.2015.993605","article-title":"Safety issues and concerns of new immunomodulators in rheumatology","volume":"14","author":"Selmi","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"B141","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.4049\/jimmunol.1402155","article-title":"IL-1 receptor type 2 suppresses collagen-induced arthritis by inhibiting IL-1 signal on macrophages","volume":"194","author":"Shimizu","year":"2015","journal-title":"J. Immunol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine"},{"key":"B143","doi-asserted-by":"publisher","first-page":"Cd012183","DOI":"10.1002\/14651858.Cd012183","article-title":"Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis","volume":"2016","author":"Singh","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B144","doi-asserted-by":"publisher","first-page":"102425","DOI":"10.1016\/j.jaut.2020.102425","article-title":"Insights into the treatment of rheumatoid arthritis: a paradigm in medicine","volume":"110","author":"Smolen","year":"2020","journal-title":"J. Autoimmun."},{"key":"B145","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.apsb.2019.11.004","article-title":"Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1 \u03b2 expression","volume":"10","author":"Son","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ymthe.2019.05.002","article-title":"Lipidoid-siRNA nanoparticle-mediated IL-1\u03b2 gene silencing for systemic arthritis therapy in a mouse model","volume":"27","author":"Song","year":"2019","journal-title":"Mol. Ther."},{"key":"B147","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/ng.582","article-title":"Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci","volume":"42","author":"Stahl","year":"2010","journal-title":"Nat. Genet."},{"key":"B148","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/ard.62.9.835","article-title":"Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases","volume":"62","author":"Stolt","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"B149","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13075-021-02431-z","article-title":"The spectrum of association in HLA region with rheumatoid arthritis in a diverse Asian population: evidence from the MyEIRA case-control study","volume":"23","author":"Tan","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"B150","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ajhg.2019.08.002","article-title":"Distinct HLA associations with rheumatoid arthritis subsets defined by serological subphenotype","volume":"105","author":"Terao","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"B151","first-page":"649","article-title":"Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis","volume":"31","author":"Tesser","year":"2004","journal-title":"J. Rheumatol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"13677","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B153","doi-asserted-by":"publisher","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B154","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11914-022-00729-8","article-title":"Inflammasomes and the IL-1 family in bone homeostasis and disease","volume":"20","author":"Tseng","year":"2022","journal-title":"Curr. Osteoporos. Rep."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/art.27366","article-title":"Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations","volume":"62","author":"van der Woude","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00296-020-04651-z","article-title":"Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis","volume":"40","author":"Vasconcelos","year":"2020","journal-title":"Rheumatol. Int."},{"key":"B157","doi-asserted-by":"publisher","first-page":"15391","DOI":"10.1038\/s41598-021-94841-x","article-title":"The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women","volume":"11","author":"Vasilev","year":"2021","journal-title":"Sci. Rep."},{"key":"B158","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/ard.2008.100867","article-title":"The natural soluble form of IL-18 receptor beta exacerbates collagen-induced arthritis via modulation of T-cell immune responses","volume":"69","author":"Veenbergen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B160","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2012-06-439026","article-title":"IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells","volume":"120","author":"Vigne","year":"2012","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.18831.1","article-title":"IL-1 in osteoarthritis: time for a critical review of the literature","volume":"8","author":"Vincent","year":"2019","journal-title":"F1000Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fimmu.2013.00177","article-title":"Unique versus redundant functions of IL-1\u03b1 and IL-1\u03b2 in the tumor microenvironment","volume":"4","author":"Voronov","year":"2013","journal-title":"Front. Immunol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3899\/jrheum.100089","article-title":"Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis","volume":"38","author":"Wang","year":"2011","journal-title":"J. Rheumatol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/1389450120666190821161259","article-title":"TNF-\u0391 and IL-6: the link between immune and bone system","volume":"21","author":"Wang","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"B166","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the treatment of pustular psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B167","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren","year":"2023","journal-title":"Br. J. Dermatol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1007\/s10067-018-4196-x","article-title":"Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study","volume":"37","author":"Wik\u00e9n","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/art.41953","article-title":"The interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial","volume":"73","author":"Winkler","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2021-220546","article-title":"Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis","volume":"81","author":"Wouters","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B173","doi-asserted-by":"publisher","first-page":"750753","DOI":"10.3389\/fimmu.2021.750753","article-title":"B cells in rheumatoid arthritis:pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"102743","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"B175","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/biom9080345","article-title":"IL-38: a new player in inflammatory autoimmune disorders","volume":"9","author":"Xie","year":"2019","journal-title":"Biomolecules"},{"key":"B176","doi-asserted-by":"publisher","first-page":"10913","DOI":"10.1073\/pnas.0801898105","article-title":"IL-33 exacerbates antigen-induced arthritis by activating mast cells","volume":"105","author":"Xu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B177","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.4049\/jimmunol.1401810","article-title":"IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation","volume":"194","author":"Ye","year":"2015","journal-title":"J. Immunol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1517\/14728222.2011.560838","article-title":"IL-33: a promising therapeutic target for rheumatoid arthritis?","volume":"15","author":"Yuan","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"B179","doi-asserted-by":"publisher","first-page":"151958","DOI":"10.1016\/j.semarthrit.2022.151958","article-title":"Interleukins and rheumatoid arthritis: bi-directional Mendelian randomization investigation","volume":"53","author":"Yuan","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"B180","doi-asserted-by":"publisher","first-page":"37008","DOI":"10.1289\/ehp10710","article-title":"Association of combined exposure to ambient air pollutants, genetic risk, and incident rheumatoid arthritis: a prospective cohort study in the UK biobank","volume":"131","author":"Zhang","year":"2023","journal-title":"Environ. Health Perspect."},{"key":"B181","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10753-012-9524-8","article-title":"IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis","volume":"36","author":"Zhang","year":"2013","journal-title":"Inflammation"},{"key":"B182","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1093\/rheumatology\/keac009","article-title":"IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype","volume":"61","author":"Zhao","year":"2022","journal-title":"Rheumatol. (Oxford)"},{"key":"B183","doi-asserted-by":"publisher","first-page":"104508","DOI":"10.1016\/j.isci.2022.104508","article-title":"Structural basis of the IL-1 receptor TIR domain-mediated IL-1 signaling","volume":"25","author":"Zhou","year":"2022","journal-title":"iScience"},{"key":"B184","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1074\/jbc.M117.805739","article-title":"Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation","volume":"293","author":"Zhou","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B185","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fcell.2020.00056","article-title":"Interleukin 37 suppresses M1 macrophage polarization through inhibition of the Notch1 and nuclear factor kappa B pathways","volume":"8","author":"Zhou","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/abbs\/gmaa174","article-title":"IL1RN promotes osteoblastic differentiation via interacting with ITGB3 in osteoporosis","volume":"53","author":"Zou","year":"2021","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1577628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:46:02Z","timestamp":1748583962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1577628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":186,"alternative-id":["10.3389\/fphar.2025.1577628"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1577628","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1577628"}}